Vincerx Pharma, Inc. (VINC)
0.0002
-0.01
(-98.47%)
USD |
OTCM |
Sep 08, 16:00
Vincerx Pharma Debt to Equity Ratio
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.18 |
| June 30, 2024 | 0.1251 |
| March 31, 2024 | -3.568 |
| December 31, 2023 | 0.223 |
| September 30, 2023 | 0.1757 |
| June 30, 2023 | 0.1253 |
| March 31, 2023 | 0.0951 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0721 |
| September 30, 2022 | 0.0614 |
| June 30, 2022 | 0.0524 |
| March 31, 2022 | 0.0453 |
| December 31, 2021 | 0.0416 |
| September 30, 2021 | 0.0414 |
| June 30, 2021 | 0.0589 |
| March 31, 2021 | 0.10 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |